Crohn’s Disease | Unmet Need | US/EU | 2025

Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors (e.g., Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe CD, while non-TNF biologics (Takeda’s Entyvio, a cell adhesion molecule [CAM] inhibitor; Johnson & Johnson Innovative Medicine’s Stelara, an interleukin [IL]-12/23 inhibitor; and AbbVie’s Skyrizi, an IL-23 inhibitor) and oral targeted therapy (AbbVie’s Rinvoq, a Janus kinase [JAK] inhibitor) are mostly used as later-line therapies, after anti-TNF failure. These agents all have safety risks and efficacy limitations, and the launch of biosimilar alternatives has only increased the complexity of CD treatment. A significant unmet need persists, particularly for patients with CD refractory to current therapies and for those with complex conditions such as fistulizing disease.

QUESTIONS ANSWERED

• What are the treatment drivers and goals for moderate to severe CD, and how do current therapies, including TNF-α inhibitors (branded and biosimilar), non-TNF biologics (i.e., Entyvio, Stelara, and Skyrizi), and JAK inhibitors (Rinvoq), perform on treatment drivers and goals?
• In addition to efficacy, which drug attributes most strongly influence physician prescribing practices, and which have the least impact?
• What are the predominant areas of unmet need and hidden opportunity in the treatment of moderate to severe CD?
• What trade-offs across clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new CD drug?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

KEY FEATURE

The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European gastroenterologists fielded in February 2025

Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Takeda, UCB, Celltrion Healthcare

Key drugs: Adalimumab, Rinvoq, Infliximab, Entyvio, Stelara, Skyrizi